MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Kymera Therapeutics Inc

Closed

SectorHealthcare

26.35 4.48

Overview

Share price change

24h

Current

Min

24.28

Max

26.79

Key metrics

By Trading Economics

Income

-8.3M

-71M

Sales

3.7M

7.4M

EPS

-0.89

Profit margin

-956.884

Employees

188

EBITDA

-8.3M

-69M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+114.94% upside

Dividends

By Dow Jones

Next Earnings

2 May 2025

Market Stats

By TradingEconomics

Market Cap

-363M

1.9B

Previous open

21.87

Previous close

26.35

News Sentiment

By Acuity

50%

50%

180 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Kymera Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

1 Nov 2024, 03:00 UTC

Top News

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

9 Jul 2024, 09:05 UTC

Top News

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

Peer Comparison

Price change

Kymera Therapeutics Inc Forecast

Price Target

By TipRanks

114.94% upside

12 Months Forecast

Average 58.83 USD  114.94%

High 97 USD

Low 49 USD

Based on 14 Wall Street analysts offering 12 month price targets forKymera Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

12

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

N/A / 30.39Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

180 / 386 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.